Ascendis Pharma Seeks FDA Approval for Transformative Achondroplasia Treatment

Ascendis Pharma has taken a major step toward revolutionizing achondroplasia treatment by submitting its New Drug Application (NDA) to the FDA for TransCon CNP (navepegritide). This once-weekly investigational therapy aims to provide continuous exposure of C-type natriuretic peptide (CNP) to support bone growth and muscle function in children with achondroplasia. The application is backed by three pivotal clinical trials and up to three years of extension study data, highlighting its potential to enhance growth velocity, improve muscle strength, and reduce leg bowing in treated children.

Dr. Aimee Shu, Chief Medical Officer at Ascendis Pharma, expressed confidence in TransCon CNP's ability to set a new standard of care, emphasizing its strong safety profile and promising results. Unlike current therapies, which require more frequent administration, TransCon CNP’s once-weekly dosing offers a more convenient, well-tolerated alternative. If approved, this therapy could provide new hope to families navigating the challenges of achondroplasia, ensuring children have a chance at healthier growth and improved mobility.